natgillin/translations-raw huggingface dataset:
Also, ulcers of mouth, throat, nose, genitals and eyes (red and swollen eyes) can occur.
Pojavijo se lahko tudi razjede v ustih, žrelu, nosu, na spolovilih in očeh (rdeče in otekle oči).
Meta-analyses also indicate consistently a significantly increased relative risk of thromboembolic events in cancer patients receiving recombinant human erythropoietin (see section 4.4).
Metaanalize so tudi dosledno pokazale značilno večje relativno tveganje trombemboličnih dogodkov pri bolnikih z rakom, ki so dobivali rekombinantni humani eritropoetin (glejte poglavje 4.4).
After any dose or schedule adjustment the haemoglobin should be monitored every one or two weeks.
Po vsaki prilagoditvi odmerka ali sheme morate hemoglobin kontrolirati na en ali dva tedna.
Part of the pre-filled pen may be broken even if you cannot see the break.
V takšnem primeru je lahko del napolnjenega injekcijskega peresnika počen, čeprav ne vidite razpoke.
Upper arm Stomach area (abdomen)
Nadlaket Področje želodca (trebuh)
In all cases, use a new pre-filled pen and contact your healthcare provider.
V vseh teh primerih uporabite nov napolnjen injekcijski peresnik in kontaktirajte zdravstvenega delavca.
• A demonstration device
• Demonstracijski pripomoček
In both groups, the dose was reduced by 40% of the previous dose (e.g., for first dose reduction, to 300 mcg in the once every three weeks group and 1.35 mcg/kg in the once weekly group) if haemoglobin increased by more than 1 g/dL in a 14-day period.
V obeh skupinah so odmerek zmanjšali za 40 % predhodnega odmerka (npr. prvo zmanjšanje na 300 µg v skupini enkrat na tri tedne in na 1,35 µg/kg v skupini enkrat na teden), če se je hemoglobin v 14-dnevnem obdobju zvišal za več kot 10 g/l.
These studies have shown a consistent unexplained statistically significant excess mortality in patients who have anaemia associated with various common cancers who received recombinant human erythropoietin compared to controls.
Te študije so pokazale dosledno, nepojasnjeno in statistično značilno večjo umrljivost med bolniki z anemijo zaradi različnih pogostih vrst raka, ki so dobivali rekombinantni humani eritropoetin, v primerjavi z bolniki v kontrolnih skupinah.
Check the expiry date on the pre-filled syringe label (EXP).
Preverite datum izteka roka uporabnosti na nalepki napolnjene injekcijske brizge (EXP).
• A poster-size instructions for use (for patients/caregivers with diminished eyesight) - includes the instructions for use located in the package leaflet in a way that patients/caregivers with diminished eyesight are informed on how to handle the pen and administer Aranesp appropriately.
• Navodila za uporabo v velikosti plakata (za bolnike/skrbnike z oslabljenim vidom) - vključujejo navodila za uporabo, ki so vključena v Navodilo za uporabo, da se bolniki/skrbniki z oslabljenim vidom seznanijo s tem, kako ravnati z injekcijskim peresnikom in si ustrezno dajati zdravilo Aranesp.
Since the liver is thought to be the principal route of elimination of darbepoetin alfa and r-HuEPO, Aranesp should be used with caution in patients with liver disease.
Vendar jetra veljajo za glavno pot eliminacije darbepoetina alfa in r-HuEPO, zato morate zdravilo Aranesp pri bolnikih z boleznimi jeter uporabljati previdno.
This study was conducted in 705 anaemic patients with non-myeloid malignancies receiving multi-cycle chemotherapy.
Študija je bila narejena pri 705 anemičnih bolnikih z nemieloičnimi malignomi, ki so dobivali več ciklusov kemoterapije.
- If you are a patient with chronic renal failure, and particularly if you do not respond properly to Aranesp, your doctor will check your dose of Aranesp because repeatedly increasing your dose of Aranesp if you are not responding to treatment may increase the risk of having a problem of the heart or the blood vessels and could increase risk of myocardial infarction, stroke and death.
- Če ste bolnik s kronično odpovedjo ledvic in še posebej, če se na zdravilo Aranesp ne odzovete primerno, vam bo zdravnik preverjal vaš odmerek zdravila Aranesp, ker lahko ponavljajoče se povečevanje odmerka zdravila Aranesp, če se na zdravilo ne odzovete, poveča tveganje za težave s srcem ali ožiljem in vam lahko poveča tveganje za srčni infarkt, možgansko kap in smrt.
• 500 micrograms once every three weeks (6.75 micrograms of Aranesp per kilogram of your body weight), or
• 500 mikrogramov enkrat na tri tedne (6,75 mikrogramov zdravila Aranesp na kilogram telesne mase) ali
Do not inject into areas where the skin is tender, bruised, red, or hard.
Ne injicirajte v predele, kjer je koža občutljiva, podpluta, pordela ali zatrdela.
There was an expected moderate (< 2 fold) increase in serum concentration as steady state was approached, but no unexpected accumulation upon repeated administration.
Ko se je bližalo stanje dinamičnega ravnovesja, je prišlo do pričakovanega zmernega (< 2-kratnega) povečanja koncentracije v serumu, ni pa bilo med ponavljajočo uporabo nobenega nepričakovanega kopičenja.
Incidence of adverse reactions from controlled clinical studies and post-marketing experience are:
Pogostnosti neželenih učinkov, zabeleženih v kontroliranih kliničnih študijah in v obdobju trženja zdravila, so:
Per the Guideline on Summary of Product
V skladu z dokumentom Guideline on Summary of
The best places to inject yourself are the top of your thighs and the abdomen.
Najprimernejši mesti za samoinjiciranje sta zgornji del stegen in trebuh.
These can appear as reddish target-like macules or circular patches often with central blisters on the trunk, skin peeling, ulcers of mouth, throat, nose, genitals and eyes and can be preceded by fever and flu-like symptoms.
Ti se lahko pojavijo kot rdečkaste, tarčam podobne kožne spremembe ali krožne lehe, pogosto z osrednjim mehurjem na trupu, lupljenje kože, razjede v ustih, žrelu, nosu, na spolovilih in očeh, pred tem se lahko pojavijo zvišana telesna temperatura in/ali gripi podobni simptomi.
This was a non inferiority study designed to rule out a 15% risk increase in tumour progression or death of epoetin alfa plus standard of care (SOC) as compared with SOC alone.
To študijo neinferiornosti so zasnovali za izključitev 15 % povečanja tveganja napredovanja tumorja ali smrti pri zdravljenju z epoetinom alfa in standardno oskrbo v primerjavi z zdravljenjem samo s standardno oskrbo.
If typical causes of non-response are excluded, and the patient has reticulocytopenia, an examination of the bone marrow should be considered.
Če ste izključili tipične vzroke neodzivnosti, bolnik pa ima retikulocitopenijo, pride v poštev pregled kostnega mozga.
- The active substance is darbepoetin alfa, r-HuEPO (erythropoietin produced by genetechnology).
- Učinkovina je darbepoetin alfa, r-HuEPO (eritropoetin, pridobljen z gensko tehnologijo).
Important: It is important to keep your skin stretched or pinched while injecting.
Pomembno: Pomembno je, da kožo med injiciranjem držite raztegnjeno ali stisnjeno.
D Prepare and clean your injection site.
D Pripravite in očistite mesto injiciranja.
Clearance of darbepoetin alfa is 1.9 mL/hr/kg (SD 0.56) and the volume of distribution (Vss) is approximately equal to plasma volume (50 mL/kg).
Očistek darbepoetina alfa je 1,9 ml/h/kg (standardni odklon 0,56), volumen porazdelitve (Vss) pa je približno enak volumnu plazme (50 ml/kg).
If you have chronic renal failure
Če imate kronično odpoved ledvic
Therapy with Aranesp can result in polycythaemia if the haemoglobin is not carefully monitored and the dose appropriately adjusted.
Zdravljenje z zdravilom Aranesp lahko povzroči policitemijo, če koncentracija hemoglobina ni natančno nadzorovana in odmerek zdravila ustrezno prilagojen.
Healthcare professionals prescribing Aranesp pre-filled pen will be provided educational materials to facilitate training patients on the correct self-administration of Aranesp.
Zdravstvenim delavcem, ki predpisujejo zdravilo Aranesp v obliki napolnjenega injekcijskega peresnika, bo zagotovljeno izobraževalno gradivo kot pomoč pri usposabljanju bolnikov o pravilnem samoinjiciranju zdravila Aranesp.
There are additional educational materials available to train you on how to self administer Aranesp pre-filled pen, a dummy demonstration device and a poster-size instructions for use for patients/caregivers with diminished eyesight.
Na voljo je tudi dodatno izobraževalno gradivo, ki vam omogoča, da se usposobite za samostojno injiciranje zdravila Aranesp v obliki napolnjenega injekcijskega peresnika, demonstracijski pripomoček brez učinkovine in navodila za uporabo v velikosti plakata za bolnike/negovalce z zmanjšanim vidom.
Step 1: Prepare A Remove the pre-filled syringe tray from the package and gather the supplies needed for your injection: alcohol wipes, a cotton ball or gauze pad, a plaster and a sharps disposal container (not included).
1. korak: Priprava A Vzemite podlogo z napolnjeno injekcijsko brizgo iz pakiranja in pripravite opremo, potrebno za injiciranje: alkoholne zložence, kosem vate ali zloženec gaze, obliž in vsebnik za ostre odpadke (ni priloženo).
• 2.25 micrograms (once weekly) of Aranesp per kilogram of your body weight.
• 2,25 mikrogramov (enkrat na teden) zdravila Aranesp na kilogram telesne mase.
Darbepoetin alfa is produced by gene-technology in Chinese Hamster Ovary Cells (CHO-K1).
Darbepoetin alfa je pridobljen z gensko tehnologijo v ovarijskih celicah kitajskega hrčka (CHO-K1).
In this study, mean (SD) terminal half-life was 74 (SD 27) hours.
V tej študiji je bil povprečni terminalni razpolovni čas 74 ur (standardni odklon 27 ur).
If the haemoglobin continues to increase, the dose should be reduced by approximately 25%.
Če se hemoglobin še naprej zvišuje, morate odmerek zmanjšati za približno 25 %.
One of the main side effects of chemotherapy is that it stops the bone marrow producing enough blood cells.
Eden glavnih neželenih učinkov kemoterapije je, da prepreči nastajanje zadostnega števila krvnih celic v kostnem mozgu.
If signs and symptoms suggestive of these reactions appear, Aranesp should be withdrawn immediately and an alternative treatment considered.
Če se pojavijo znaki ali simptomi, ki kažejo na takšne reakcije, je treba zdravilo Aranesp nemudoma prenehati uporabljati in razmisliti o drugačnem zdravljenju.
Two of the studies recruited patients who were being treated with chemotherapy.
Dve sta zajeli bolnike, zdravljene s kemoterapijo.
In the once every three weeks group, 72% of patients required dose reductions.
V skupini enkrat na tri tedne je zmanjšanje odmerka potrebovalo 72 % bolnikov, v skupini enkrat na teden pa 75 % bolnikov.
For instructions on use of the pre-filled pen, please read the section at the end of this leaflet.
Navodila za uporabo napolnjenega injekcijskega peresnika preberite v poglavju na koncu tega navodila.
This leaflet was last revised in
Navodilo je bilo nazadnje revidirano dne.
Aranesp has no or negligible influence on the ability to drive and use machines.
Zdravilo Aranesp nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
Erythropoietin is produced in your kidneys and encourages your bone marrow to produce more red blood cells.
Eritropoetin nastaja v ledvicah in spodbuja kostni mozeg, da tvori več rdečih krvnih celic.
F Stretch or pinch your injection site to create a firm surface.
F Raztegnite ali stisnite mesto injiciranja, da boste ustvarili trdno površino.
Your doctor will take regular blood samples to measure how your anaemia is responding and may adjust your dose as necessary.
Zdravnik vam bo redno jemal kri za meritve, ki bodo pokazale, kako dobro se anemija odziva, in bo lahko odmerek prilagodil, kot bo potrebno.
If you notice a spot of blood you may gently dab it away with a cotton ball or tissue.
Če opazite kapljico krvi, jo lahko previdno popivnate s koščkom vate ali papirnatim robčkom.
Identified adverse reactions associated with Aranesp are hypertension, stroke, thromboembolic events, convulsions, allergic reactions, rash/erythema and pure red cell aplasia (PRCA); see section 4.4.
Med ugotovljenimi neželenimi učinki, povezanimi z zdravilom Aranesp, so hipertenzija, možganska kap, trombembolični dogodki, konvulzije, alergijske reakcije, izpuščaj/eritem in čista aplazija rdečih celic (PRCA); glejte poglavje 4.4.
The safety and effectiveness of once every three weeks dosing of Aranesp therapy in reducing the requirement for red blood cell transfusions in patients undergoing chemotherapy was assessed in a randomised, double-blind, multinational study.
Varnost in učinkovitost zdravljenja z zdravilom Aranesp enkrat na tri tedne za zmanjšanje potrebe po transfuzijah eritrocitov so pri bolnikih na kemoterapiji raziskali v randomizirani, dvojno slepi mednarodni študiji.
The reported risk of thrombotic vascular events (TVEs) should be carefully weighed against the benefits to be derived from treatment with darbepoetin alfa particularly in patients with pre-existing risk factors for TVE, including obesity and prior history of TVEs (e.g., deep venous thrombosis, pulmonary embolism, and cerebral vascular accident).
Poročano tveganje za trombotične žilne dogodke (TVE - Thrombotic Vascular Events) je treba skrbno pretehtati glede na pričakovano korist zdravljenja z darbepoetinom alfa, predvsem pri bolnikih z obstoječimi dejavniki tveganja za TVE, vključno z debelostjo in TVE v anamnezi (npr. globoka venska tromboza, pljučna embolija in cerebrovaskularni dogodki).
Patients starting dialysis during treatment with Aranesp should be closely monitored for adequate control of their haemoglobin.
Bolnike, ki med zdravljenjem z zdravilom Aranesp začnejo z dializo, je treba skrbno nadzirati glede ustrezne urejenosti hemoglobina.
Do not use the pre-filled pen if any part appears cracked or broken.
Ne uporabite napolnjenega injekcijskega peresnika, če se kateri koli del zdi zdrobljen ali zlomljen.
Instructions for use: Guide to parts
Navodilo za uporabo: Sestavni deli
Your normal dialysis routine will not affect the ability of Aranesp to treat your anaemia.
Vaše običajno dializno zdravljenje ne bo vplivalo na učinkovitost zdravila Aranesp pri zdravljenju anemije.
SJS/TEN can appear initially as reddish target-like spots or circular patches often with central blisters on the trunk.
SJS/TEN se lahko sprva pojavita kot rdečkaste, tarčam podobne kožne spremembe ali krožne lehe, pogosto z osrednjim mehurjem na trupu.
When changing the route of administration the same dose must be used and the haemoglobin monitored every one or two weeks so that the appropriate dose adjustments can be made to keep the haemoglobin at the desired level.
Če spremenite pot uporabe, morate uporabiti isti odmerek, hemoglobin pa kontrolirati na en ali dva tedna, da boste odmerek lahko prilagajali za ohranitev želene ravni hemoglobina.
• Aranesp is given as an injection into the tissue just under the skin (subcutaneous injection).
• Zdravilo Aranesp se daje kot injekcija v tkivo tik pod kožo (subkutano injiciranje).
Your doctor has given you Aranesp (an anti-anaemic) to treat your anaemia.
Zdravnik vam je predpisal zdravilo Aranesp (zdravilo proti slabokrvnosti) za zdravljenje anemije.
If the patient has developed a severe cutaneous skin reaction such as SJS or TEN due to the use of Aranesp, treatment with Aranesp must not be restarted in this patient at any time.
Če se bolniku zaradi uporabe zdravila Aranesp pojavi huda kožna reakcija, na primer SJS ali TEN, se takšnemu bolniku ne sme nikoli več uvesti zdravila Aranesp.
Push down
Pritisnite dol
In an European observational registry study which enrolled 319 paediatric patients with chronic kidney disease (13 (4.1%) patients < 1 year of age, 83 (26.0%) patients 1-< 6 years of age, 90 (28.2%) patients 6-< 12 years of age, and 133 (41.7%) patients ≥ 12 years of age) receiving darbepoetin alfa, mean haemoglobin concentrations ranging between 11.3 and 11.5 g/dL and mean weight-adjusted darbepoetin alfa doses remained relatively constant (between 2.31 mcg/kg month and 2.67 mcg/kg month) over the study period for the entire study population.
V evropski opazovalni registrski študiji, ki je zajela 319 pediatričnih bolnikov s kronično boleznijo ledvic (13 (4,1 %) bolnikov, starih < 1 leto, 83 (26,0 %) bolnikov, starih 1 - < 6 let, 90 (28,2 %) bolnikov, starih 6 - < 12 let, in 133 (41,7 %) bolnikov, starih ≥ 12 let) zdravljenih z darbepoetinom alfa, sta med obdobjem študije ostala povprečna koncentracija hemoglobina v razponu od 113 do 115 g/l in povprečni na telesno maso prilagojeni odmerek darbepoetina alfa (od 2,31 µg/kg na mesec do 2,67 µg/kg na mesec) razmeroma stalna v celotni študijski populaciji.
The longer terminal half-life of darbepoetin alfa administered subcutaneously compared to intravenously is due to subcutaneous absorption kinetics.
Daljši terminalni razpolovni čas subkutano apliciranega darbepoetina alfa v primerjavi z intravensko apliciranim je posledica kinetike subkutane absorpcije.
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 0.375 ml
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT 0,375 ml
Due to intra-patient variability, occasional individual haemoglobin values for a patient above and below the desired haemoglobin level may be observed.
Zaradi variabilnosti med bolniki se lahko občasno pri posameznem bolniku pojavijo vrednosti hemoglobina, ki so višje ali nižje od želene koncentracije.
Aranesp may be administered subcutaneously by the patient or a carer after being trained by a doctor, nurse or pharmacist.
Zdravilo Aranesp si lahko daje podkožno bolnik sam ali oseba, ki zanj skrbi, potem ko so ju za to usposobili zdravnik, medicinska sestra ali farmacevt.
Haemoglobin concentrations were corrected to ≥ 10 g/dL in > 98% (p < 0.001) of paediatric patients administered darbepoetin alfa once weekly and 84% (p = 0.293) once every two weeks.
Koncentracija hemoglobina se je popravila na ≥ 100 g/l pri > 98 % (p < 0,001) pediatričnih bolnikov, ki so dobivali darbepoetin alfa vsak teden, in pri 84 % (p = 0,293) tistih, ki so ga dobivali vsaka dva tedna.
Manufacturer Amgen NV Telecomlaan 5-7 1831 Diegem Belgium
Proizvajalec Amgen NV Telecomlaan 5-7 1831 Diegem Belgija
Characteristics (Revision 2, September 2009), frequency of adverse reactions identified in the post-marketing setting was determined using the “Rule of three”.
Product Characteristics (revizija 2, september 2009) je bila pogostnost neželenih učinkov, prepoznanih v obdobju trženja zdravila, določena z uporabo “pravila trojke”.
It is unknown whether Aranesp is excreted in human milk.
Ni znano, ali se zdravilo Aranesp pri človeku izloča v materino mleko.
Aranesp 25, 40, 60, 100, 200, 300 micrograms solution for injection in vial Aranesp is administered either subcutaneously or intravenously as described in the posology.
Aranesp 25, 40, 60, 100, 200, 300 mikrogramov raztopina za injiciranje v viali Zdravilo Aranesp se uporablja subkutano ali intravensko, kot je opisano v poglavju Odmerjanje.
Carefully lift the pre-filled pen straight up out of the carton.
Previdno dvignite napolnjeni injekcijski peresnik naravnost iz škatle.
1 Adverse reactions identified in the post-marketing environment.
1 Neželeni učinki prepoznani v obdobju trženja zdravila.
• Store the pre-filled pen in the refrigerator (2ºC - 8ºC).
• Napolnjen injekcijski peresnik shranjujte v hladilniku (2 °C - 8 °C).
Patients should be monitored closely to ensure that the lowest approved effective dose of Aranesp is used to provide adequate control of the symptoms of anaemia whilst maintaining a haemoglobin concentration below or at 12 g/dL (7.5 mmol/L).
Bolnike je treba skrbno nadzirati, da bi zagotovili uporabo najmanjšega odobrenega učinkovitega odmerka zdravila Aranesp, potrebnega za ustrezno obvladanje simptomov anemije ob hkratnem vzdrževanju koncentracije hemoglobina pod ali na 120 g/l (7,5 mmol/l).
A paradoxical decrease in haemoglobin and development of severe anaemia associated with low reticulocyte counts should prompt to discontinue treatment with epoetin and perform anti-erythropoietin antibody testing.
V primeru paradoksnega znižanja hemoglobina in nastanka hude anemije, ki jo spremlja majhno število retikulocitov, je treba zdravljenje z epoetinom prekiniti in opraviti testiranje antieritropoetinskih protiteles.
PHARMACEUTICAL FORM AND CONTENTS 1 single use vial
FARMACEVTSKA OBLIKA IN VSEBINA 1 viala za enkratno uporabo
Caution should be exercised with escalation of Aranesp doses in patients with chronic renal failure, since high cumulative epoetin doses may be associated with an increased risk of mortality, serious cardiovascular and cerebrovascular events.
Bolnikom s kronično odpovedjo ledvic je treba odmerke zdravila Aranesp povečevati previdno, ker so visoki kumulativni odmerki epoetina lahko povezani s povečanim tveganjem za umrljivost ter resne kardiovaskularne in cerebrovaskularne dogodke.
Dose changes in the maintenance phase of treatment should not be made more frequently than every two weeks.
Med vzdrževalnim zdravljenjem odmerka ne smete spreminjati pogosteje kot na dva tedna.
There is therefore consistent evidence to suggest that there may be significant harm to patients with cancer who are treated with recombinant human erythropoietin.
Obstajajo konsistentni dokazi, da lahko bolnikom z rakom zdravljenje z rekombinantnim humanim eritropoetinom škoduje.
The following side effects have been experienced by some patients taking Aranesp:
Naslednji neželeni učinki so se pojavili pri nekaterih bolnikih, ki so dobivali zdravilo Aranesp:
These antibodies have been shown to cross-react with all erythropoietic proteins, and patients suspected or confirmed to have neutralising antibodies to erythropoietin should not be switched to Aranesp (see section 4.8).
Ugotovljeno je, da ta protitelesa navzkrižno reagirajo z vsemi eritropoetičnimi beljakovinami; bolnikov, pri katerih obstaja sum ali pri katerih je potrjeno, da imajo nevtralizirajoča protitelesa proti eritropoetinu, ne smete prevesti na zdravilo Aranesp (glejte poglavje 4.8).
Epoetins are growth factors that primarily stimulate red blood cell production.
Epoetini so rastni dejavniki, ki stimulirajo predvsem nastajanje rdečih krvnih celic.
These parameters were consistent with dose linear pharmacokinetics over a wide dose range (0.5 to 8 mcg/kg weekly and 3 to 9 mcg/kg every two weeks).
Ti parametri se skladajo s farmakokinetiko, linearno povezano z odmerkom, v širokem odmernem območju (od 0,5 do 8 µg/kg na teden in od 3 do 9 µg/kg na dva tedna).
If after a dose reduction, haemoglobin continues to increase, the dose should be temporarily withheld until the haemoglobin begins to decrease, at which point therapy should be reinitiated at approximately 25% lower than the previous dose.
Če se hemoglobin po zmanjšanju odmerka še naprej zvišuje, uporabo začasno prekinite, dokler se hemoglobin ne začne zniževati; potem terapijo znova uvedite z odmerkom, približno 25 % manjšim od prejšnjega.
When substituting Aranesp for r-HuEPO the haemoglobin should be monitored every one or two weeks and the same route of administration should be used.
Pri zamenjavi r-HuEPO z zdravilom Aranesp je treba hemoglobin kontrolirati na en ali dva tedna in uporabiti isto pot aplikacije.
Your doctor will tell you how much and how often you must take Aranesp in order to maintain a haemoglobin level between 10 and 12 g/dL.
Zdravnik vam bo povedal, koliko zdravila Aranesp morate uporabljati in kako pogosto, da boste koncentracijo hemoglobina ohranili med 100 in 120 g/l.
Data from 809 patients receiving Aranesp in European clinical studies were analysed to assess the dose required to maintain haemoglobin; no difference was observed between the average weekly dose administered via the intravenous or subcutaneous routes of injection.
Za določitev odmerka, potrebnega za vzdrževanje hemoglobina, so analizirali 809 bolnikov, ki so zdravilo Aranesp dobivali v evropskih kliničnih študijah; med povprečnim tedenskim odmerkom, uporabljenim intravensko ali subkutano, niso ugotovili razlik.
Special warnings: - If you have symptoms which include unusual tiredness and a lack of energy this could mean you have pure red cell aplasia (PRCA), which has been reported in patients.
Posebna opozorila: - Če imate simptome, med katerimi sta nenavadna utrujenost in pomanjkanje energije, to lahko pomeni, da imate čisto aplazijo rdečih celic.